Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19.

Babafemi O TaiwoKara W ChewCarlee MoserDavid Alain WohlEric S DaarJonathan Z LiAlexander L GreningerChristoph BauschThomas LukeKeila HooverGene NeytmanMark J GigantiMaxine OlefskyArzhang Cyrus JavanCourtney V FletcherJoseph J EronJudith S CurrierMichael D HughesDavey M Smithnull null

Published in: The Journal of infectious diseases (2023)

SAB-185 was safe and generally well tolerated and demonstrated modest antiviral activity in predominantly low-risk non-hospitalized adults with COVID-19.

Keyphrases

coronavirus disease
sars cov
african american